<DOC>
	<DOCNO>NCT01414634</DOCNO>
	<brief_summary>Open-label , single center , phase I clinical trial ass safety , tolerability preliminary efficacy vivo mechanisms action i.v . administration autologous peripheral blood mononuclear cell ( PBMC ) chemically couple cocktail contain seven immunodominant myelin peptide T cell response demonstrable early RR MS patient .</brief_summary>
	<brief_title>Establish Tolerance In MS With Peptide-Coupled , Peripheral Blood Mononuclear Cells</brief_title>
	<detailed_description>Open-label , single center , phase I dose-escalation study ass safety , tolerability preliminary efficacy vivo mechanisms action single infusion autologous peripheral blood mononuclear cell chemically couple seven myelin peptide ( MOG1-20 , MOG35-55 , MBP13-32 , MBP83-99 , MBP111-129 , MBP146-170 , PLP139-154 ) Multiple Sclerosis patient off-treatment standard therapy . Neurological , magnetic resonance imaging , laboratory , immunological examination perform assess safety , tolerability , vivo mechanism action regimen .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>1 . Between age 18 55 year . 2 . Patients relapsingremitting ( Phase I/II ) secondary progressive MS ( Phase I ) accord publish criterion 3 . EDSS score 1 5.5 . 4 . Patients offtreatment standard therapy ( interferonbeta , glatiramer acetate , natalizumab , mitoxantrone ) 5 . Patients able provide write , informed consent prior test protocol , include screen baseline investigation consider part routine patient care . 6 . Disease duration â‰¤ 5 year ( Only Phase II ) 1 . Diagnosis secondaryprogressive ( Phase II ) primaryprogressive MS , define publish diagnostic criterion . 2 . Abnormal screening/baseline blood test exceed limit define 3 . Pregnant breastfeed female . 4 . History sign immunodeficiency . 5 . Concurrent clinically significant ( determined investigator ) cardiac , immunological , pulmonary , neurological , renal major disease . 6 . Splenectomy 7 . History HIV positive HIV antibody test 8 . Serology indicate active Hepatitis B C infection . 9 . Patients cognitive impairment unable provide write , informed consent prior test protocol , include screen baseline investigation consider part routine patient care</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>